iNtRON Biotechnology (048530.KQ) Earnings Analysis

iNtRON Biotechnology (048530.KQ) next reports earnings on 2026-08-12, consensus EPS 16.56 KRW. Last quarter (2026-02-12) it missed with EPS -130.27 KRW vs -20.36 KRW est (-539.8%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E -8.70.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 048530.KQ next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate16.56 KRW
Revenue estimate7.32B

048530.KQ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-12-130.27 KRW-20.36 KRW-539.8%Miss
2025-11-12-53 KRWn/an/an/a
2025-08-18-32.79615 KRWn/an/an/a
2025-05-15-60.00044 KRWn/an/an/a
2025-03-11-45.08259 KRWn/an/an/a
2024-11-18-40 KRWn/an/an/a
2024-08-1417.46 KRWn/an/an/a

Beat rate: 0/1 (0%) over reported quarters with consensus data.

048530.KQ valuation and analyst view

Trailing P/E-8.70
Trailing EPS-304.0794 KRW
Price / book1.22
Dividend yield3.98%
Market cap75.99B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is iNtRON Biotechnology (048530.KQ)'s next earnings date?

iNtRON Biotechnology is next scheduled to report on 2026-08-12, with a consensus EPS estimate of 16.56 KRW and revenue estimate of 7.32B.

Did 048530.KQ beat earnings last quarter?

In its 2026-02-12 report, 048530.KQ posted EPS of -130.27 KRW versus a -20.36 KRW estimate — a miss of 539.8%.

What is 048530.KQ's earnings track record?

Over the last 1 reported quarters with consensus data, 048530.KQ beat estimates 0 times (0%).

What is 048530.KQ's current P/E ratio and EPS?

048530.KQ trades at a trailing P/E of -8.70 on trailing EPS of -304.07939650802194 KRW.

What do analysts rate 048530.KQ?

048530.KQ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.